[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560-1160", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 125, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 66, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 49, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 631042, "exercisedValue": 0, "unexercisedValue": 285755}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 65, "title": "Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 719206, "exercisedValue": 0, "unexercisedValue": 2986052}, {"maxAge": 1, "name": "Dr. Mark  Smythe Ph.D.", "age": 58, "title": "Founder & VP Technology", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling", "age": 52, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 59, "title": "Executive VP & Chief Drug Discovery and Preclinical Development Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 52, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Abha  Bommireddi", "title": "Executive Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 43.59, "open": 43.56, "dayLow": 43.56, "dayHigh": 45.34, "regularMarketPreviousClose": 43.59, "regularMarketOpen": 43.56, "regularMarketDayLow": 43.56, "regularMarketDayHigh": 45.34, "beta": 2.165, "trailingPE": 16.57353, "forwardPE": -33.14706, "volume": 600093, "regularMarketVolume": 600093, "averageVolume": 670382, "averageVolume10days": 526380, "averageDailyVolume10Day": 526380, "bid": 44.96, "ask": 45.15, "bidSize": 100, "askSize": 100, "marketCap": 2655419392, "fiftyTwoWeekLow": 13.72, "fiftyTwoWeekHigh": 48.0, "priceToSalesTrailing12Months": 8.321069, "fiftyDayAverage": 42.7782, "twoHundredDayAverage": 32.79445, "currency": "USD", "enterpriseValue": 2102392704, "profitMargins": 0.53257, "floatShares": 43684818, "sharesOutstanding": 58904600, "sharesShort": 3520031, "sharesShortPriorMonth": 3278065, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0598, "heldPercentInsiders": 0.01176, "heldPercentInstitutions": 1.02641, "shortRatio": 4.7, "shortPercentOfFloat": 0.060599998, "bookValue": 9.212, "priceToBook": 4.893617, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 169954000, "trailingEps": 2.72, "forwardEps": -1.36, "enterpriseToRevenue": 6.588, "enterpriseToEbitda": 13.722, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PTGX", "underlyingSymbol": "PTGX", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "firstTradeDateEpochUtc": 1470922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "db1f1c69-f5b8-3245-b848-39f5038697fa", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.08, "targetHighPrice": 65.0, "targetLowPrice": 43.0, "targetMeanPrice": 52.71, "targetMedianPrice": 51.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 563996992, "totalCashPerShare": 9.575, "ebitda": 153208000, "totalDebt": 10971000, "quickRatio": 13.598, "currentRatio": 13.731, "totalRevenue": 319120000, "debtToEquity": 2.027, "revenuePerShare": 5.278, "returnOnAssets": 0.20351, "returnOnEquity": 0.40688, "freeCashflow": 143727376, "operatingCashflow": 231542000, "grossMargins": 1.0, "ebitdaMargins": 0.48009998, "operatingMargins": -9.30958, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-14"}]